Lund, Sweden - 26 March 2012 - BioInvent International AB (OMXS: BINV)

At BioInvent's Annual General Meeting on 26 March, CEO Svein Mathisen informed the shareholders about the Company's progress. His presentation concluded that the advances of the clinical portfolio in 2011 will lead to a decisive 2012 with readouts from at least three of the four existing clinical programs. The AGM resolved in accordance with the Board's proposals to amend the provision in the articles of association regarding the auditor's term and authorize the Board of Directors to issue new shares .

The AGM voted in favour of adopting the income statements and balance sheets for the Group and the parent company. The AGM also decided that the profits at the disposal of the AGM, amounting to SEK 76 509 360 after deduction of the year's loss of SEK -67 052 501, should be carried forward.

The AGM discharged the Board members and the President and CEO from liability and reelected the ordinary board members Lars Backsell, Carl Borrebaeck, Lars Ingelmark, Elisabeth Lindner, Svein Mathisen, Björn O. Nilsson and Kenth Petersson. Björn O. Nilsson was reelected Chairman of the Board.

Further, the AGM resolved that the Board's fees shall remain unchanged at SEK 400,000 for the Chairman of the Board and SEK 160,000 for each of the other members of the Board not employed by the Company. In addition hereto, it was decided that the fee for the Chairman of the Audit Committee shall amount SEK 50,000, that the fee for each of the other members in the Audit Committee shall amount to SEK 40,000 and that the fee for each of the members in the Remuneration Committee shall amount to SEK 20,000. Fee for Committee work shall however not be paid to the Chairman of the Board.

In accordance with the proposal of the Board of Directors, the AGM further resolved to amend the provision in the articles of association as regards the auditor's term into a two years term.

The AGM also resolved to elect the auditing company KPMG AB as the Company's Auditor, for a term of two years. KPMG AB has informed that the authorized public accountant Alf Svensson will be auditor in charge.

The AGM further resolved in accordance with the Board's proposal on guidelines for remuneration of executive management.

Last, the AGM authorized the Board of Directors to resolve on the issue of not more than the number of new shares equivalent to 10 percent of the registered share capital (as per the date of the resolution on the issue of new shares), on one or several occasions during the period up to the next annual general meeting. The issue may take place with or without a deviation from the shareholders' preferential right and with or without provisions on contribution in kind or set-off or any other terms. The purpose of the authorisation is to increase the Company's financial flexibility and to enable acquisitions by payment of shares. If the Board of Directors resolves on an issue with deviation from the shareholders' preferential right the reason may be to add the Company new owners of strategic importance to the Company and/or the acquisition of other companies or businesses. At a deviation from the shareholders' preferential right, the issue rate shall be determined in accordance with market conditions. Other terms may be resolved by the Board of Directors.

                                                                 -- END --

To the editors:

About BioInvent
BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company currently has four clinical development projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances to strengthen the product pipeline and increase the likelihood of success. These partners include Genentech, Human Genome Sciences, Roche and ThromboGenics.

The company's competitive position is underpinned by n-CoDeR®, a proprietary antibody development platform. The scope and strength of this platform is also utilised by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at www.bioinvent.com.

For further information, please contact:

BioInvent International AB
Svein Mathisen                                                     Sten Westerberg
President & CEO                                                  Vice President, Investor Relations
Phone:+46 (0)46 286 85 67                                    Phone: +46 (0)46 286 85 52
Mobile: +46 (0)708 97 82 13                                   Mobile: +46 (0)768 68 50 09
E-mail: [email protected]                    E-mail: [email protected]

College Hill (media enquiries)
Melanie Toyne Sewell, Daniel Gooch
Phone: +44 (0)20 7866 7866
Rebecca Skye Dietrich
Phone: +1 (857) 241 0795
E-mail: [email protected]

BioInvent International AB (publ)
Co. reg. No. 556537-7263,
Visiting address: Sölvegatan 41
Mailing address: SE-223 70 LUND
Phone: +46 (0)46 286 85 50
[email protected]
www.bioinvent.com

Legal disclaimer
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same was as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 5.45 p.m. CET, on 26 March, 2012.